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Abstract
Problem: Heart failure has a growing impact on Americans, and this contributes to an
increased number of patients requiring treatment for advanced heart failure. Typical
treatment options may include cardiac transplant or the implantation of a left ventricular
assist device (LVAD). The use of an LVAD requires sterile management of an external
driveline site. Driveline infections are a common complication in this patient population
and can lead to chronic complications. There are no published guidelines on the
management of the driveline site. This project aimed to provide evidence that can be used
in the establishment of standardized guidelines for driveline site care. Methods: This QI
initiative compared driveline infections between two different dressing change protocols
at a single midwestern hospital. Data was compared from the years 2017-2021 with the
change in dressing protocol occurring in 2019. A retrospective medical record review
was conducted, and the data was analyzed using independent sample t-tests to measure
significance. A confidence interval of 95% was used. Results: A bi-weekly dressing
change protocol using a pre-packaged kit, clear occlusive dressing, silver-impregnated
ring, and driveline stabilization device resulted in a reduction of LVAD driveline
infections (with significance p-value <0.001) when compared to the retired method.
Further research could be conducted on how patient compliance impacts driveline
infections. Implications for Practice: The results of this QI initiative may be useful in the
creation of standardized published guidelines for LVAD driveline site care.
Keywords: left ventricular assist device (LVAD) care, driveline site infections,
LVAD driveline site infections
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Driveline Infection Rates Between Two Different Dressing Methods
Introduction
Background and Significance
Heart failure is a common chronic condition in the United States and a leading
cause of hospital readmission with up to 50% of patients readmitted within six months or
discharge (O’Connor, 2017). There are many treatment options for heart failure, and
some patients require a cardiac transplant for their condition. As the population ages,
there is a large number of patients diagnosed with heart failure that no longer qualify for
transplant due to age and/or the number of co-morbidities. Projections estimate that by
2030, there will be two million Americans with heart failure over the age of eighty
(DeFilippis et al., 2019). An alternative therapy to transplant for these patients who may
not qualify is the implantation of a left ventricular assist device (LVAD). This device
helps improve quality of life and reduce symptoms associated with heart failure. As the
population with heart failure gets older, the use of the LVAD may become more
prevalent.
A ventricular assist device consists of an implanted pump connected via a
driveline to an external power source and controller. The pump is inserted into the apex
of the heart during open-heart surgery. The pump takes blood from the ventricle of the
heart and moves it through a tube to the aorta to continuously pump it through the body.
A driveline runs from the pump, exiting through the abdominal wall, to an external
controller connected to a power source. The goal of the implantation is either destination
therapy to help control heart failure symptoms and prolong life or as a bridge to
transplant. Using an LVAD can improve a patient’s one-year survival rate from 25% to
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50% compared to guideline medical therapy (Hove et al., 2020). Guideline-directed
medical therapy consists of a complex medication regime including beta-blockers,
angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.
It requires strong adherence and close follow-up to manage treatment. The four-year
survival rate for patients who receive an LVAD is similar to that of a cardiac transplant
(Hove et al., 2020).
There is sufficient evidence to support using a ventricular assist device to manage
heart failure, but it is not without risk. The internal pump connects to a driveline that exits
through the body to an external power source. This exit site requires specific care and
attention to prevent infection. Unfortunately, a driveline-site infection is the most
common adverse occurrence in this patient population and can pose long-term
complications (Juraszek et al., 2021). Within the first year of implant, 18.1% of patients
with an LVAD will experience a driveline infection, and 11.9% of LVAD patients will
experience a driveline infection beyond the first year (Hove et al., 2020). Driveline
infections can pose a chronic issue and place the patient at a higher risk for stroke. As
many as 13% of patients in a study of LVAD patients with driveline infections
experienced a stroke within six weeks of their infection and suffered reduced cumulative
survival as a result (Cho et al., 2019). The high incidence of driveline infections
emphasizes the importance of an effective care management protocol of the driveline site.
Purpose
Currently, there are no published standardized guidelines on exit site dressing care
protocol for an LVAD driveline. Therefore, the purpose of this quality improvement (QI)
project was to retrospectively compare LVAD driveline infection rates between two
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different dressing change protocols to determine which method results in fewer infections
in the first year following LVAD placement. This project aim was to provide evidence to
assist in the development of specific dressing change guidelines for the management of
an LVAD driveline.
This QI initiative sought to answer the following question: “In adults ages 55
years or older that have a ventricular assist device, what is the effect of using a driveline
dressing kit and bi-weekly dressing change compared to the previous method with daily
dressing change, on driveline infection rates over the first year of implantation?” The
outcomes that were measured include the driveline infection rates of each dressing
change protocol, the type of LVAD, and when the infection occurred.
The previous method of dressing changes for LVAD patients at a Midwest urban
acute facility consisted of a daily dressing change using sterile technique. The old
dressing is removed, and the driveline insertion site is cleansed initially with
chlorhexidine and sterile water-soaked gauze, followed by gauze only soaked in sterile
water. The site is dried with sterile gauze and re-dressed with split gauze, 4x4 gauze, and
covered with Hypafix® (water-resistant hypoallergenic adhesive) tape. The driveline site
covered with gauze is not visible between dressing changes. The driveline is anchored to
the skin using the Centurion® urinary catheter holder. This dressing change protocol will
be referred to in this QI project as the “retired protocol.”
The new method of driveline care was initiated in Fall 2019 and consists of a prepackaged kit that includes all necessary dressing and cleaning supplies. The kit contains
hand sanitizer packages for glove changes, two sets of clean gloves, adhesive remover,
two sets of sterile gloves, two chlorhexidine swab sticks, a skin barrier applicator, a
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silver-impregnated dressing ring, a transparent Tegaderm™ dressing, and a new
Centurion® urinary catheter anchor device. The old dressing is removed using clean
gloves and adhesive remover. Hand hygiene is performed, and sterile gloves are donned.
The skin surrounding the driveline site is cleansed with the first chlorhexidine swab. The
driveline itself is cleaned using the second chlorhexidine swab. The silver-impregnated
ring is then placed around the driveline exit site, and skin barrier is applied. Finally, the
transparent dressing is applied and provides visibility of the driveline site. These dressing
changes are completed twice a week. This method will be referred to as the “current
protocol.”
Literature Review
A literature search was conducted using the following databases: PubMed,
Cumulative Index of Nursing and Allied Health Literature (CINAHL) and SUMMON.
Search terms included “LVAD AND driveline infections,” “LVAD driveline care,” and
“LVAD dressing AND infection.” The trajectory and criteria used for article
identification and selection for this review can be found in Appendix A. Fourteen articles
underwent critical review for this QI project and include one practice guideline, three
systematic reviews, four correlational studies, three mixed-methods studies, two
descriptive/non-experimental studies, and one quasi-experimental study.
A significant gap in the available literature is the lack of established standardized
guidelines for the dressing care and management of LVAD driveline sites. The lack of
standardized guidelines leaves the decision on dressing care to the providers’ clinical
expertise, available evidence on wound management, and facility provided supplies. In
addition, reference can be made to other sterile line management guidelines.
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Through analysis of the available literature, five emerging themes or aspects of
driveline care impacting the incidence of infection were identified. These include the type
of cleaning agent, type of dressing material, presence of an anchor device to secure the
driveline, frequency of dressing change, and use of a pre-packaged dressing kit.
Cleaning Agent
Cleaning agents identified for the driveline site care include chlorhexidine,
hydrogen peroxide, iodine, Octanisept®(solution of octenide hydrochloride and alcohol),
and a polymyxin-trimethoprim solution (Juraszek et al., 2021). Studies using
chlorhexidine solution reported lower driveline infection rates, as low as 5.4% (Koken et
al., 2021). The Octanisept® solution had infection rates of 11%, while the polymyxintrimethoprim had infection rates of 13.8% (Koken et al., 2021). Iodine solutions also had
higher infection rates and was often cited as the alternative agent to chlorhexidine for
patients with an allergy to that agent. While three articles used chlorhexidine, there were
discrepancies in how the agent was used. Many articles did not mention how these agents
were used to clean, while one mentioned soaking gauze in Octanisept® and letting it sit
on the skin (Juraszek et al., 2021).
Dressing
The type of dressings applied to driveline insertion sites were not often specified,
but usually included occlusive dressing materials including Tegaderm™, Hypafix®, or a
silver-based dressing (Yoshi et al., 2018). In addition, one study included dressing types
that were impregnated with polyhexamethylene biguanide, an antiseptic. A silver-based
dressing was the most often used antiseptic dressing in LVAD patients (Juraszek et al.,
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2021). There were no studies that referenced how the type of dressing influenced
infection rates.
Anchoring Device
The next aspect identified affecting driveline infection rates was the type of
fixation device used. Trauma to the driveline site is a significant risk for infection. Using
a stabilization device helps prevent movement of the driveline (Bejko et al., 2018). The
two most often mentioned methods for stabilization include the Centurion® urinary
catheter holder and an abdominal binder. One study mentioned that driveline fixation has
the most considerable impact on infection risk and utilized surgical immobilization via
sutures for thirty days after implant (Bernhardt et al., 2020). The retired and current
protocols at the study facility used the Centurion® urinary catheter holder to anchor the
driveline. This device works by adhering to the abdomen and securing the driveline in
place to prevent tension on the exit site. Both protocols changed the anchor device on an
as-needed basis. The use of an abdominal binder was associated with a higher infection
rate (Koken et al., 2021).
Dressing Change Frequency
Although dressing change frequency was not found to have a direct impact on
driveline infection rates, it may influence patient adherence to dressing care. In one study,
dressing changes could be completed daily and then every two or three days after the site
had time to heal (Schlöglhofer et al., 2020). Variation in dressing change frequency
ranges from every three days or daily if there was drainage from the site. Another study
used daily dressing changes from the time of implant through the duration of the LVAD
(Imamura et al., 2017).
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Pre-Packaged Kit
Another common theme between articles was the use of a dressing kit. The
dressing kit contains all necessary supplies, including sterile gloves, the cleaning agent,
and dressings. The kits were easy to use and resulted in fewer driveline infections
(DeFilippis et al., 2019). Although two articles mentioned using a kit in managing the
driveline site, details were not provided on what was included in the kit or how the care
was managed prior to using the kit.
An additional factor identified in the literature that may contribute to driveline
infection is the position of the driveline. The internal portion of the driveline has a velour
interface section designed for better adherence internally. If patients experience trauma to
the site, this velour section may become external. Patients with the velour completely
implanted have a 50% less chance of developing a driveline infection (Zinoviev et al.,
2020).
A few articles discussed additional strategies to mitigate driveline infections and
the associated complications. One suggestion to lower infection risk is to use a
specialized nurse to provide education and training to patients (Rahal et al., 2019). This
education would include daily care instructions as well as recognizing alarms and
troubleshooting. Some LVAD providers mention using long-term antimicrobial
suppression to lower the risk of complications from driveline infections. The decision for
suppression therapy is often left to clinical expertise, but it has been shown to positively
affect those who experience driveline infections frequently (Radcliffe et al., 2020).
Because there is little published evidence on the management of LVAD driveline
sites, a review of the American Society of Anesthesiologists (2020) published guidelines
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on central line access was included for comparison. These guidelines recommend
chlorhexidine as the cleaning agent, using a transparent bio-occlusive dressing, and
securing the line with an anchoring device (American Society of Anesthesiologists,
2020). It was mentioned that an adhesive fixation device should be used when applicable,
and a dressing impregnated with chlorhexidine should be used if tolerated by the patient
(American Society of Anesthesiologists, 2020). Although a central line is different from a
driveline, it is helpful to review the management of central access lines for comparison.
Analysis of Evidence
The articles selected provide valuable information on the dressing care of
driveline sites. Strengths of the evidence include strong follow-up with and minor loss or
participants in each study. Although studies included had small sample sizes of less than
75 people, they appear to be a good representation of the LVAD population for the site
studied. Most, if not every, patient with an LVAD were included in the studies. In
addition, articles provided new evidence on a topic and patient population that has been
lacking in the literature. Many articles discussed care and management of the same type
of LVADs, reducing an additional variable and making it easier to gather cumulative
data.
It was difficult to compare studies due to lack of consistency in driveline site care
from study to study. Better descriptions of how each cleaning agent was used would have
been useful. All articles selected were retrospective studies. A prospective study about
driveline infections would allow for the generation of more robust evidence.
Gaps in the Literature
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No studies identified compared different dressing protocols within the same
patient group or facility and resulting driveline infection rate. No two articles were found
that use the same dressing method, with each driveline management protocol differing in
some way. The literature reviewed all discussed the importance of cleaning, covering,
and stabilizing the driveline, but with significant variation in methods and infection
outcomes. Further studies are needed which include a description of how cleaning agents
are applied. Due to the lack of standardization, there is a need to determine which
dressing protocols result in lower infection rates.
Additional gaps include information on patient adherence and compliance. Patient
adherence to dressing change protocols could potentially be a factor affecting driveline
infection rates.
It is worth exploring whether using antimicrobial dressings impact infection rates
when controlling all other factors. A few articles used a transparent adhesive dressing,
while others used an antimicrobial one, and it would be helpful to know if the
antimicrobial dressing reduces infection rates.
Finally, although the use of pre-packaged kits was discussed, the studies reviewed
do not identify specific kit contents. Additional studies comparing kit contents and
impact on infection and patient compliance would provide more clarity when developing
a standardized LVAD dressing change protocol.
Theoretical Framework for Change
The Iowa Model is a valuable framework in guiding nurse-led change in the
clinical setting and was selected for the QI initiative. This model provides a clear path for
implementing change triggered by a clinician’s question of current practice standards
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(Melnyk & Fineout-Overholt, 2019). The Iowa Model provides an easily applied
framework for developing an evidence-based practice standard. Clinical questions can be
addressed using the evidence-based practice process and provide feedback loops to
continue progress. The first step in applying this model is identifying the problem and
stating the purpose (Melnyk & Fineout-Overholt, 2019). Once the purpose is established,
the researcher puts together a team. Evidence is identified and synthesized in order to
create a practice change design (Melnyk & Fineout-Overholt, 2019). The design change
is piloted and evaluated to see if it is appropriate to adopt it into practice (Melnyk &
Fineout-Overholt, 2019). The final step of this framework is to disseminate the results
with other professionals. Evidence sharing can be through presentations or publications,
and it helps promote the use of evidence-based practice in the clinical setting.
Method
Design
This QI initiative evaluated the use of evidence-based practice in the care of
LVAD patients to reduce driveline infection rates by improving dressing management.
This initiative was a comparative descriptive study with no experimental variable
introduced. The study was correlational as it described the relationship between the
dressing protocols and the incidence of driveline infections in the LVAD population. The
data was collected via a retrospective medical record review to measure the incidence of
driveline infections.
Setting
This quality improvement initiative took place in an urban hospital located in a
medium-sized metropolitan area located in the Midwest. The hospital belongs to a system
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consisting of four metropolitan hospitals, multiple community hospitals, a rehabilitation
facility, and a hospice house. This hospital has over 600 physicians that span more than
60 medical specialties, and it is nationally ranked in cardiac care.
Sample
Due to the specific qualities needed for this initiative, purposeful sampling was
used to select patients to be included. The potential participants included patients with a
HeartMate II, HeartMate III, or HeartWare ventricular assist device implanted. The
inclusion criteria were patients with an LVAD, patients 55 or older, and patients who had
a driveline infection between 2017-2021 and were within their first year of implant. The
exclusion criteria included patients younger than 55 years old and patients who do not
have an LVAD.
Approval Processes
The approval processes included approval by an appointed doctoral committee
and two Institutional Review Boards (IRB). IRB training was completed. IRB approval
was obtained from the hospital site where data was collected, and from the DNP
candidate’s (primary investigator) educational facility. There were no identified risks for
the patient samples as their identity was kept anonymous. De-identified data collected
was stored on the investigator’s private laptop which was kept at the investigator’s home.
Data Collection/Analysis
The data that was collected included the patient’s age, type of LVAD implanted,
and the incidence of a driveline infection, including when the driveline infection
occurred. More specifically, infection rates were collected on LVAD patients who had an
infection between the years 2017-2021 and were within the first year of implant. There
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was a total of 42 patients included in the retired protocol sample and a total of 54 patients
included in the current protocol sample. This information was gathered through a
retrospective review of medical records. Data analysis was conducted via independent ttests to compare the effect of the different dressing protocols on infection rates.
Procedures
In order to gather information on the incidence of driveline infection, a
retrospective review of the medical records for all LVAD patients was conducted.
Patients who had their LVAD driveline infection between 2017-2021 were excluded
based on stated exclusion criteria, and those that met the inclusion criteria were included
in the study. At this point, the medical record was reviewed to assess whether the
driveline infection occurred during the retired protocol or with the current protocol for
driveline care. The rates of infection were compared using Excel spreadsheets to organize
the information.
Results
Upon completion of the retrospective medical record review, a total of 16
driveline infections had occurred in the specified time and qualifications. Table 1
provides a breakdown of the number of infections occurring in each year. The average
age of the patients affected was seventy-two years old, and the most common organism
identified as methicillin susceptible staphylococcus aureus (MSSA). Patient
demographics are identified in Appendix B. The majority of patients were treated with a
course of intravenous antibiotics although some required surgical treatment in addition to
intravenous medication. Of the 15 patients who experienced a driveline infection under
the retired protocol, seven of the patients had the Heartmate II LVAD, seven had the
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HeartWare LVAD, and one had the Heartmate III. The patient who had a driveline
infection under the new protocol had a Heartmate III LVAD. While there was a much
lower incidence of infection in the Heartmate III, it also was not used clinically until
2019, which was the same year that the dressing protocol was changed. The average time
after implant for the onset of infection was seven months but ranged from three months to
eleven months.
Table 1
Breakdown of Infection Totals per Year
Protocol

Infection Total (2017-2021) Total LVAD Patients Infection Ratio

Retired

15

42

36%

Current

1

54

2%

In order to test for significance in the protocol change, an independent t-test was
completed using Statistical Package for the Social Sciences (SPSS) software. A 95%
confidence interval was used with a p-value of .05 to measure significance. After
completing the independent t-test, a p-value of <0.001 was resulted. This data can be
found in Figure 1.
Figure 1
SPSS Data Output
Independent Samples

T-test for Equality of

95% Confidence

Test

Means

Interval of the
Difference
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t

df

Sig.
(2-

Mean

Std. Error

Lower

Upper

Difference Difference

tailed)
Equal

4.607

107

<.001

.28946

.06283

.16491

.41400

4.221

54.042

<.001

.28946

.06858

.15197

.42695

Variance
Assumed
Equal
Variance
Not
Assumed

The result reflects a significant difference in infection rates between the retired
and current dressing protocols. The analysis results of the quality improvement project
support that the current protocol reduced infection rates in the LVAD population when
compared with the retired protocol.
Discussion
The implementation of a bi-weekly dressing change using a pre-packaged
dressing change kit reduced driveline infections in LVAD patients when compared with a
daily dressing change and no pre-packaged kit. Patients who were within their first year
of implant experienced significantly fewer driveline infections when using the current
protocol for driveline site dressing change. The use of an antimicrobial dressing (silver
impregnated ring) may have aided in the prevention of microbial infection at the sterile
driveline site. In addition, decreasing the number of times the sterile site is exposed to
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open air may help to prevent potential additional exposure to bacteria. The changes in
dressing care also help reduce the impact of human error. A daily dressing change put
more reliance on the person changing the dressing to maintain sterility at all times. After
the frequency was decreased to twice weekly, the chance for human error and
contamination during a dressing change appear to be decreased.
In addition to decreasing the frequency of dressing changes, the use of a prepackaged kit appears to enhance compliance and reduce human error. The pre-packaged
dressing change kit provides for a step-by-step process, making it easier to complete. In
addition, the kits provide hand sanitizer which may help remind the person completing
the dressing change to complete hand hygiene to reduce contamination. The dressing kit
clearly separates the clean portion from the sterile portion of the dressing change. This kit
helps to ensure that the person completes all of the necessary steps required prior to
donning sterile gloves.
The evidence supporting the use of a pre-packaged dressing kit combined with biweekly dressing changes can improve outcomes and reduce driveline site infections. This
data supports the continuation of the current protocol for dressing change. In addition,
thorough patient education prior to implantation is warranted. The practice change made
in the dressing care for LVAD patients may reduce human error that can contribute to
infection. Ensuring a thorough education on the care of the LVAD and the driveline site
may help to further reduce infections. This data may be useful in establishing
standardized and published guidelines for LVAD driveline site care. Standardizing
driveline site care for all LVAD patients can improve patient outcomes by lowering
infection rates.

LVAD INFECTION RATES
18
One limitation to this project is that there was no control for the driveline
material. For patients who experience pulling on their driveline, they risk exposing a
velour material meant to stay internal for adherence. The exposure of the velour material
increases the risk for a driveline infection (Imamura et al., 2017). In addition, patient
compliance is another variable that could not be controlled for this project. Future studies
to determine the impact of patient compliance with site dressing changes on driveline
infection rates is recommended. In addition, it is recommended to study how the
frequency of dressing changes impact patient compliance.
This quality improvement (QI) practice change should be implemented on a
permanent basis. In addition, continued surveillance of infection rates is recommended.
In addition, expanding this study to other hospitals that implant LVADs would help to
aggregate more data that would indicate the results of this study are generalizable and can
support a standardized approach to driveline site care.
Conclusion
A patient who requires an LVAD has already been impacted by serious health
issues and failing medical treatments. Implantation of LVADs helps to improve quality of
life in heart failure patients and can also prolong their lives. The driveline site is a
common place for infection which can pose major complications for the patient. These
pumps require specific management to prevent infection at the driveline site. The
protocols for management of driveline sites have not been standardized; however, two
different dressing change methods were compared in a single Midwest facility. The
retrospective medical record review revealed that using a pre-packaged dressing kit with
bi-weekly dressing changes significantly decreased driveline infection rates when

LVAD INFECTION RATES
19
compared to a daily dressing change without a pre-packaged kit. Data provided in this
study may help to contribute to the development of published guidelines for driveline
sites in LVAD patients to improve overall outcomes and reduce driveline infection rates.
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Appendix A

Identification

Prisma Diagram of Literature Review
Records identified through database
searching
1990-2021
PubMed: n=17
CINAHL: n=249
Summon: n=17,637

C
(n = )

Additional records identified through
other sources

(n = 1)

Records after duplicates removed

Screening

(n =8,769)

Inclusion Criteria
Publications less than or equal to 5
years old
Peer-reviewed articles
Articles from academic journals
Articles discussing LVAD care
and/or LVAD infection

Records screened

Eligibility

(n =8,769)

Full-text articles assessed
for eligibility

Included

(n =61)

Exclusion Criteria
Publications over 5 years old
Full article unavailable
Articles with patients that don’t have
an LVAD
Articles not discussing LVAD
management or infection

Studies included in systematic
review
(n =14)
Practice Guidelines: n=1
Systematic Review: n=3
Correlational: n=4
Mixed Methods: n=3
Descriptive/Non-experimental: n=2
Quasi-Experimental: n=1
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Appendix B
Data Collection Excel Spreadsheet
Patient
Identifier
A81674
A47167
A82166
A10516
A61771
A11178
A31175
A74177
A85177
A10617
A14518
A91884
A39187
A44186
A63187
A57216

LVAD
Year
Year of
Type
Implanted Infection
Heartmate
II
2016
2017
Heartmate
II
2016
2017
Heartmate
II
2016
2017
Heartmate
II
2016
2017
Heartmate
II
2017
2018
HeartWare
2017
2018
HeartWare
2017
2018
HeartWare
2017
2018
Heartmate
II
2017
2018
Heartmate
II
2017
2018
HeartWare
2018
2018
HeartWare
2018
2019
HeartWare
2018
2019
Heartmate
III
2018
2019
HeartWare
2018
2019
Heartmate
III
2021
2021

LVAD age at
Infection

Dressing Method

Type of
Bacteria

3 months

Retired

MRSA

3 months

Retired

MRSA

8 months

Retired

MSSA

11 months

Retired

Unknown

7 months
2 months
3 months
5 months

Retired
Retired
Retired
Retired

MSSA
Unknown
MSSA
S.Epi

9 months

Retired

MSSA

11 months
10 months
11 months
8 months

Retired
Retired
Retired
Retired

Unknown
MSSA
MSSA
Proteus

6 months
10 months

Retired
Retired

Unknown
Pseudomonas

3 months

Current

Unknown

